Suppr超能文献

冷缺血和炎症性肿瘤微环境对临床癌症样本中 PI3K/AKT 和 MAPK 通路激活模式检测的影响。

Effects of cold ischemia and inflammatory tumor microenvironment on detection of PI3K/AKT and MAPK pathway activation patterns in clinical cancer samples.

机构信息

Roche Pharma Research and Early Development, Penzberg, Germany.

出版信息

Int J Cancer. 2012 Oct 1;131(7):1621-32. doi: 10.1002/ijc.27422. Epub 2012 Feb 28.

Abstract

The accuracy of common markers for PI3K/AKT and MAPK pathway activation in preclinical and clinical cancer biomarker studies depends on phosphoepitope stability and changes of phosphorylation under ischemia. Herein, we define conditions under which phosphoepitope-specific duplex immunohistochemistry (IHC) on formalin-fixed, paraffin-embedded tumor tissues reflects pathway activation in situ as accurately as possible, and identify activation patterns linked to mutational status, pathway dependency and tumor microenvironment in clinical tumor samples, cell culture and xenograft tissues. Systematically assessing robustness of pAKT, pERK1/2, pMEK1/2 and pmTOR detection and related markers in xenograft tissues exposed to ischemia, we show that control of preprocessing and ischemia times allows accurate interpretation of staining results. Phosphorylation patterns were then analyzed in 33 xenograft models and in 58 cases with breast cancer, including 21 paired samples of core-needle biopsies with corresponding mastectomy specimens, and 37 mastectomy samples obtained under rigorously controlled conditions minimizing ischemia time. Patterns of pAKT and pERK1/2 staining (predominant PI3K/AKT, predominant MAPK and concomitant activation) were associated with sensitivity to pathway inhibition and partially with the mutational status in cell lines and corresponding xenograft tumors. In contrast, no clear correlation between mutational status and staining patterns was observed in clinical breast cancer samples, suggesting that interaction with the human tumor microenvironment may interfere with the use of phosphoepitope-specific IHC as potential markers for pathway dependency. In contrast to core needle biopsies, surgically resected breast cancer samples showed evidence of severe signal changes comparable to those effects observed in xenograft tumors exposed to controlled ischemia.

摘要

在临床癌症生物标志物研究中,常见的 PI3K/AKT 和 MAPK 通路激活标志物的准确性取决于磷酸化表位的稳定性和缺血条件下磷酸化的变化。在此,我们定义了在福尔马林固定、石蜡包埋的肿瘤组织上进行磷酸化表位特异性双探针免疫组化(IHC)以尽可能准确地反映原位通路激活的条件,并确定与突变状态、通路依赖性和肿瘤微环境相关的激活模式在临床肿瘤样本、细胞培养和异种移植组织中。我们系统地评估了在经历缺血的异种移植组织中 pAKT、pERK1/2、pMEK1/2 和 pmTOR 检测及其相关标志物的稳健性,结果表明预处理和缺血时间的控制可以准确解释染色结果。然后,我们分析了 33 种异种移植模型和 58 例乳腺癌病例中的磷酸化模式,包括 21 对核心针活检的配对样本和相应的乳房切除术标本,以及在严格控制条件下获得的 37 例乳房切除术样本,以最大程度地减少缺血时间。pAKT 和 pERK1/2 染色的模式(PI3K/AKT 优势、MAPK 优势和共同激活)与对通路抑制的敏感性相关,部分与细胞系和相应异种移植瘤中的突变状态相关。相比之下,在临床乳腺癌样本中未观察到突变状态与染色模式之间的明显相关性,这表明与人类肿瘤微环境的相互作用可能会干扰磷酸化表位特异性 IHC 作为潜在通路依赖性标志物的使用。与核心针活检相比,手术切除的乳腺癌样本显示出与在受控缺血下暴露的异种移植瘤中观察到的相似的严重信号变化证据。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验